Tokyo Tape
Sign in
← PeptiDream

Quarterly report · Q2

4587.TEDINET S100RNSH
Period2023-01-01 → 2023-06-30
Filed2023-08-10
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed

Amended by S100S6V5 (2023-11-09).

Key figures · 62
MetricValuePeriodScopeSource row
Revenue¥9.4bn2023-01-01 → 2023-06-30Cons.Revenue IFRS
Revenue¥4.5bn2023-04-01 → 2023-06-30dCons.Revenue IFRS
Revenue¥26.9bn2022-01-01 → 2022-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥5.0bn2022-01-01 → 2022-06-30Cons.Revenue IFRS
Revenue¥4.6bn2022-04-01 → 2022-06-30dCons.Revenue IFRS
Operating income−¥986m2023-01-01 → 2023-06-30Cons.Operating profit loss IFRS
Operating income−¥720m2023-04-01 → 2023-06-30dCons.Operating profit loss IFRS
Operating income−¥1.7bn2022-01-01 → 2022-06-30Cons.Operating profit loss IFRS
Operating income−¥499m2022-04-01 → 2022-06-30dCons.Operating profit loss IFRS
Profit before tax−¥1.1bn2023-01-01 → 2023-06-30Cons.Profit loss before tax IFRS
Profit before tax−¥711m2023-04-01 → 2023-06-30dCons.Profit loss before tax IFRS
Profit before tax¥6.7bn2022-01-01 → 2022-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax−¥1.6bn2022-01-01 → 2022-06-30Cons.Profit loss before tax IFRS
Profit before tax−¥467m2022-04-01 → 2022-06-30dCons.Profit loss before tax IFRS
Net income (owners)−¥729m2023-01-01 → 2023-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥480m2023-04-01 → 2023-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥7.6bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥1.1bn2022-01-01 → 2022-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥303m2022-04-01 → 2022-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income−¥729m2023-01-01 → 2023-06-30Cons.Profit loss IFRS
Net income−¥480m2023-04-01 → 2023-06-30dCons.Profit loss IFRS
Net income¥7.6bn2022-01-01 → 2022-12-31Cons.Profit loss IFRS (5-year summary)
Net income−¥1.1bn2022-01-01 → 2022-06-30Cons.Profit loss IFRS
Net income−¥303m2022-04-01 → 2022-06-30dCons.Profit loss IFRS
Total assets¥57.7bnat 2023-06-30Cons.Assets IFRS
Total assets¥63.9bnat 2022-12-31Cons.Assets IFRS
Total assets¥52.4bnat 2022-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥26.7bnat 2023-06-30Cons.Liabilities IFRS
Total liabilities¥31.8bnat 2022-12-31Cons.Liabilities IFRS
Net assets / equity¥31.0bnat 2023-06-30Cons.Equity IFRS
Net assets / equity¥32.0bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥24.7bnat 2022-06-30Cons.Equity IFRS
Net assets / equity¥25.4bnat 2021-12-31dCons.Equity IFRS
Equity (owners)¥31.0bnat 2023-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥32.0bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥24.7bnat 2022-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥11.2bnat 2023-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥5.2bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥6.4bnat 2022-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.7bnat 2021-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥8.8bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow−¥83m2022-01-01 → 2022-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow−¥493m2022-01-01 → 2022-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥798m2023-01-01 → 2023-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥27.4bn2022-01-01 → 2022-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥26.7bn2022-01-01 → 2022-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥2.3bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥20.8bn2022-01-01 → 2022-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥21.6bn2022-01-01 → 2022-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-5.622023-01-01 → 2023-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥-3.72023-04-01 → 2023-06-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥58.192022-01-01 → 2022-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-8.722022-01-01 → 2022-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥-2.332022-04-01 → 2022-06-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥-5.622023-01-01 → 2023-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥-3.72023-04-01 → 2023-06-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥58.142022-01-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-8.722022-01-01 → 2022-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥-2.332022-04-01 → 2022-06-30dCons.Diluted earnings loss per share IFRS
Equity ratio53.8%at 2023-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio50.2%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio47.0%at 2022-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 22
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-06-30−¥30m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-06-30−¥30m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥1.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥1.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2023-01-01 → 2023-06-30−¥1.2bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥8.0bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥8.0bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2023-01-01 → 2023-06-30¥30m
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-06-30¥228m
—segment totalrevenue2023-01-01 → 2023-06-30¥9.5bn
—segment totalrevenue external2023-01-01 → 2023-06-30¥9.4bn
—segment totalrevenue intersegment2023-01-01 → 2023-06-30¥30m
—segment totalsegment profit2023-01-01 → 2023-06-30−¥941m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2022-01-01 → 2022-06-30¥1.1bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2022-01-01 → 2022-06-30¥1.1bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2022-01-01 → 2022-06-30−¥1.4bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-06-30¥3.9bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-06-30¥3.9bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-06-30¥114m
—segment totalrevenue2022-01-01 → 2022-06-30¥5.0bn
—segment totalrevenue external2022-01-01 → 2022-06-30¥5.0bn
—segment totalsegment profit2022-01-01 → 2022-06-30−¥1.3bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 634
ItemContextValueUnit
Cash and cash equivalents IFRSPrior1YearInstant5247665000JPY
Cash and cash equivalents IFRSCurrentQuarterInstant11188589000JPY
Trade and other receivables ca IFRSPrior1YearInstant16589145000JPY
Trade and other receivables ca IFRSCurrentQuarterInstant4528719000JPY
Other financial assets ca IFRSPrior1YearInstant6243000JPY
Other financial assets ca IFRSCurrentQuarterInstant6244000JPY
Inventories ca IFRSPrior1YearInstant2678699000JPY
Inventories ca IFRSCurrentQuarterInstant2645131000JPY
Income taxes receivable ca IFRSPrior1YearInstant－JPY
Income taxes receivable ca IFRSCurrentQuarterInstant327735000JPY
Other current assets ca IFRSPrior1YearInstant550958000JPY
Other current assets ca IFRSCurrentQuarterInstant451296000JPY
Current assets IFRSPrior1YearInstant25072713000JPY
Current assets IFRSCurrentQuarterInstant19147716000JPY
Property plant and equipment IFRSPrior1YearInstant18125415000JPY
Property plant and equipment IFRSCurrentQuarterInstant17567853000JPY
Goodwill IFRSPrior1YearInstant8370677000JPY
Goodwill IFRSCurrentQuarterInstant8370677000JPY
Intangible assets IFRSPrior1YearInstant2232554000JPY
Intangible assets IFRSCurrentQuarterInstant2167756000JPY
Investments accounted for using equity method IFRSPrior1YearInstant399728000JPY
Investments accounted for using equity method IFRSCurrentQuarterInstant305891000JPY
Other financial assets nca IFRSPrior1YearInstant6122214000JPY
Other financial assets nca IFRSCurrentQuarterInstant6633554000JPY
Deferred tax assets IFRSPrior1YearInstant3435235000JPY
Deferred tax assets IFRSCurrentQuarterInstant3395766000JPY
Retirement benefit asset nca IFRSPrior1YearInstant65441000JPY
Retirement benefit asset nca IFRSCurrentQuarterInstant67443000JPY
Other non current assets nca IFRSPrior1YearInstant41218000JPY
Other non current assets nca IFRSCurrentQuarterInstant47836000JPY
Non current assets IFRSPrior1YearInstant38792486000JPY
Non current assets IFRSCurrentQuarterInstant38556781000JPY
Assets IFRSPrior1YearInstant63865200000JPY
Assets IFRSCurrentQuarterInstant57704497000JPY
Trade and other payables cl IFRSPrior1YearInstant4080097000JPY
Trade and other payables cl IFRSCurrentQuarterInstant2919285000JPY
Borrowings cl IFRSPrior1YearInstant2690653000JPY
Borrowings cl IFRSCurrentQuarterInstant2193246000JPY
Other financial liabilities cl IFRSPrior1YearInstant344882000JPY
Other financial liabilities cl IFRSCurrentQuarterInstant254903000JPY
Income taxes payable cl IFRSPrior1YearInstant2325030000JPY
Income taxes payable cl IFRSCurrentQuarterInstant－JPY
Provisions cl IFRSPrior1YearInstant27649000JPY
Provisions cl IFRSCurrentQuarterInstant18150000JPY
Contract liabilities cl IFRSPrior1YearInstant669757000JPY
Contract liabilities cl IFRSCurrentQuarterInstant1082868000JPY
Other current liabilities cl IFRSPrior1YearInstant892332000JPY
Other current liabilities cl IFRSCurrentQuarterInstant548096000JPY
Total current liabilities IFRSPrior1YearInstant11030403000JPY
Total current liabilities IFRSCurrentQuarterInstant7016551000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-12-31pass rounding
balance sheet identityconsolidated 2023-06-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass